Human epidermal growth factor receptor 2 Positive Breast Cancer
Showing 76 - 100 of >10,000
Locally Advanced (Inoperable) or Metastatic Breast Cancer Trial in Worldwide (Capivasertib, Matched Capivasertib Placebo,
Recruiting
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Capivasertib
- +3 more
-
Los Angeles, California
- +76 more
Nov 25, 2022
Metastatic Breast Cancer Trial in Guangyuan, Guangzhou (Pyrotinib combined with fulvestrant)
Unknown status
- Metastatic Breast Cancer
- Pyrotinib combined with fulvestrant
-
Guangyuan, China
- +1 more
Dec 19, 2020
NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Mar 24, 2023
Primary Breast Cancer Trial in Beijing (Vinorelbine)
Recruiting
- Primary Breast Cancer
-
Beijing, Beijing, ChinaPeking University Cancer Hospital
Oct 26, 2020
Breast Tumors, Breast Cancer, Adenocarcinomas Trial run by the NCI (AdHER2/neu DC Vaccine)
Completed
- Breast Neoplasms
- +3 more
- Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 12, 2022
Metastatic Breast Cancer Trial in United States (Pertuzumab, Trastuzumab)
Completed
- Metastatic Breast Cancer
-
Tucson, Arizona
- +15 more
Dec 3, 2021
Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)
Not yet recruiting
- Triple-Negative Breast Cancer
- Trastuzumab Deruxtecan
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jul 12, 2023
Among HR+/HER2- mBC Receiving Palbociclib Combination Therapy in
Active, not recruiting
- Breast Cancer
-
New York, New YorkPfizer United States
Mar 18, 2021
Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)
Not yet recruiting
- Breast Neoplasms
- Disitamab Vedotin
- Toripalimab
-
Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
- +2 more
Oct 23, 2023
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in
Recruiting
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
-
Canton, OhioGabrail Cancer and Research Center
Jul 21, 2023
HER2-negative Early Breast Cancer Trial in Beijing (neoadjuvant chemo upon in vitro PTC drug sensitivity screening for triple
Recruiting
- HER2-negative Early Breast Cancer
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
-
Beijing, ChinaPeking University People's Hospital
Mar 27, 2022
Metastatic Breast Cancer (MBC) Trial in Nanjing, Shanghai (Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate
Recruiting
- Metastatic Breast Cancer (MBC)
- Paclitaxel Polymeric Micelles for Injection
- +5 more
-
Nanjing, Jiangsu, China
- +2 more
Nov 21, 2023
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast
Terminated
- Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
-
Phoenix, Arizona
- +39 more
Jun 21, 2022
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Metastatic Breast Cancer Trial in Italy (Both blood and tissues collection for patients with metastatic breast cancer HER2+
Completed
- Metastatic Breast Cancer
- Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.
-
Bergamo, Italy
- +8 more
Feb 9, 2023
Breast Cancer Trial in Oslo, Trondheim (Aromatase Inhibitor, Bevacizumab, Epirubicine)
Completed
- Breast Cancer
- Aromatase Inhibitor
- +6 more
-
Oslo, Norway
- +2 more
Jan 5, 2023
HER2-positive Breast Cancer, Breast Cancer Metastatic Trial in Kansas City, Overland Park, Lee's Summit (Palbociclib 75mg,
Active, not recruiting
- HER2-positive Breast Cancer
- Breast Cancer Metastatic
- Palbociclib 75mg
- +5 more
-
Kansas City, Kansas
- +4 more
Nov 23, 2020
Breast Cancer, Tumor Metastasis Trial in Houston (Trastuzumab, RAD001)
Completed
- Breast Cancer
- Neoplasm Metastasis
-
Houston, TexasUT MD Anderson Cancer Center
Sep 30, 2022